Soligenix Inc
SNGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.48M
Close$
$1.46
278.2% upside
Current Fair Value
278.2% upsideUndervalued by 278.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.48 Million |
|---|---|
| Enterprise Value | $-4,023,608.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.14 |
| Beta | 1.92 |
| Outstanding Shares | 15,951,949 |
Return
| Return on Equity | -84.99% |
|---|---|
| Return on Assets | -53.80% |
| Return on Invested Capital | -157.51% |
Valuation & Multiples
| P/E Ratio | -0.29 |
|---|---|
| PEG | 0.29 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.37 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.08 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.87%▲ 3.31% |
|---|---|
| Total Invested | $370,768▲ 20.60% |
| Investors Holding | 150% |
ESG Score
No data
About Soligenix Inc
18 employees
CEO: Christopher Schaber Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.